Clinical Development ConcernsClinical hold for LN-145 in NSCLC after a report of a Grade 5 serious adverse event (patient death).
Financial Health RisksIovance reports a cash burn of $320-340 million, which is projected to fund operations until the second half of 2025.
Regulatory And Safety IssuesThe label includes a boxed warning noting risk of treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.